Invacare (NYSE: IVC) reported earnings on July 25. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended June 30 (Q2), Invacare beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue shrank significantly. Non-GAAP earnings per share dropped to a loss. GAAP loss per share grew.

Gross margins grew, operating margins shrank, net margins dropped.

Revenue details
 Invacare recorded revenue of $351.8 million. The one analyst polled by S&P Capital IQ expected revenue of $320.0 million on the same basis. GAAP reported sales were 23% lower than the prior-year quarter's $454.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
 EPS came in at -$0.27. The two earnings estimates compiled by S&P Capital IQ predicted -$0.20 per share. Non-GAAP EPS were -$0.27 for Q2 against $0.30 per share for the prior-year quarter. GAAP EPS were -$0.29 for Q2 compared to -$0.06 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
 For the quarter, gross margin was 28.2%, 50 basis points better than the prior-year quarter. Operating margin was -1.6%, 470 basis points worse than the prior-year quarter. Net margin was -2.6%, 220 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $325.0 million. On the bottom line, the average EPS estimate is -$0.17.

Next year's average estimate for revenue is $1.33 billion. The average EPS estimate is -$1.00.

Investor sentiment
 The stock has a five-star rating (out of five) at Motley Fool CAPS, with 51 members out of 65 rating the stock outperform, and 14 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 15 give Invacare a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Invacare is buy, with an average price target of $20.00.

Is Invacare the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.